Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.89 USD | +1.40% | +0.35% | +191.18% |
04-18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
03-06 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+191.18% | 114M | |
+3.93% | 111B | |
+11.38% | 105B | |
-12.84% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.29% | 16.96B | |
+2.41% | 13.7B | |
+35.95% | 12.45B |
- Stock Market
- Equities
- RZLT Stock
- News Rezolute, Inc.
- Canaccord Genuity Adjusts Price Target on Rezolute to $17 From $16, Maintains Buy Rating